Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urea/Lactic Acid Cream and Vitamin B6 for Capecitabine-Induced Hand-Foot Syndrome
NCT00296036Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2006
- Primary completion
- Jul 2009
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of urea + lactic acid and pyridoxine in hand-foot syndrome (HFS) (6 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Incidence and Severity of Capecitabine-caused Palmar-plantar Erythrodysesthesia at 3 weeks. Started Jun 2006; status: completed.
02
Drugs
urea + lactic acidpyridoxine
03
Conditions
hand-foot syndrome (HFS)
Beyond the preview
Go deeper on NCT00296036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00296036.